Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 1/20 | 0.57 |
| ▸ | PTGFR | P43088 | 6/20 | 0.54 |
| ▸ | PTGER3 | P43115 | 5/20 | 0.54 |
| ▸ | PTGER4 | P35408 | 6/20 | 0.49 |
| ▸ | PTGER1 | P34995 | 3/20 | 0.49 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | PTGIR | P43119 | 2/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.49 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.49 |
| ▸ | ESR1 | P03372 | 1/20 | 0.49 |
| ▸ | PGR | P06401 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL129365 | 1.00 | MGLL (0.57) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL129363 | 1.00 | MGLL (0.57) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL125098 | 0.88 | PTGFR (0.67) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL125097 | 0.88 | PTGFR (0.67) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL125099 | 0.88 | PTGFR (0.67) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL126531 | 0.87 | MGLL (0.52) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL126530 | 0.87 | MGLL (0.52) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL126529 | 0.87 | MGLL (0.52) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL124113 | 0.81 | PTGER4 (0.64) | MGLLPTGFRPTGER3PTGER4PTGER1 | |
| SCHEMBL125666 | 0.81 | PTGER4 (0.64) | MGLLPTGFRPTGER3PTGER4PTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1390036-B1 | PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2012-03-07 | — | — | EP | claimed |
| US-6670485-B2 | Vision disorders | ALLERGAN, INC. | 2003-12-30 | — | — | US | claimed |
| US-6531504-B2 | Such as (Z)-7-((1R,2R,3R)-2-((E)-(S)-5-(3-Chlorobenzo(b) thiophen-2-yl)-3-hydroxypent-1-enyl)-3-hydroxy-5-oxocyclopentyl)hept-5-enoic acid for treatment of hypertension and/or glaucoma | ALLERGAN, INC. | 2003-03-11 | — | — | US | claimed |
| US-20020177620-A1 | Prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN SALES, INC. | 2002-11-28 | — | — | US | claimed |
| EP-1390036-B1 | PROSTANOIC ACID DERIVATIVES AS AGENTS FOR LOWERING INTRAOCULAR PRESSURE | ALLERGAN INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-6670485-B2 | Vision disorders | ALLERGAN, INC. | 2003-12-30 | — | — | US | disclosed |
| US-20030105155-A1 | Prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN SALES, INC. | 2003-06-05 | — | — | US | disclosed |
| US-6531504-B2 | Such as (Z)-7-((1R,2R,3R)-2-((E)-(S)-5-(3-Chlorobenzo(b) thiophen-2-yl)-3-hydroxypent-1-enyl)-3-hydroxy-5-oxocyclopentyl)hept-5-enoic acid for treatment of hypertension and/or glaucoma | ALLERGAN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020177620-A1 | Prostanoic acid derivatives as agents for lowering intraocular pressure | ALLERGAN SALES, INC. | 2002-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020177620-A1 | Prostanoic acid derivatives as agents for lowering intraocular pressure | PTGIR, PTGS2, CBR1 | MGLL 3813/4885PTGFR 26/4885PTGER3 68/4885 |
| US-20030105155-A1 | Prostanoic acid derivatives as agents for lowering intraocular pressure | PTGIR, PTGS2, CBR1 | MGLL 3796/4885PTGFR 26/4885PTGER3 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.